{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:11:02Z","timestamp":1785510662844,"version":"3.56.0"},"reference-count":27,"publisher":"Akademiai Kiado Zrt.","issue":"7","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,2,15]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    A sz\u00edvel\u00e9gtelens\u00e9g a cardiovascularis morbidit\u00e1s \u00e9s\n                    mortalit\u00e1s egyik f\u0151 oka, a betegs\u00e9g nagym\u00e9rt\u00e9kben rontja a betegek\n                    \u00e9letmin\u0151s\u00e9g\u00e9t. Az SGLT2-g\u00e1tl\u00f3k randomiz\u00e1lt, kontroll\u00e1lt klinikai vizsg\u00e1latok\n                    alapj\u00e1n jelent\u0151sen jav\u00edtj\u00e1k a kimeneteleket \u00e9s cs\u00f6kkentik a t\u00fcneteket.\n                    Ugyanakkor a val\u00f3 \u00e9letb\u0151l sz\u00e1rmaz\u00f3 adatok kulcsfontoss\u00e1g\u00faak e gy\u00f3gyszercsoport\n                    hat\u00e1soss\u00e1g\u00e1nak \u00e9s biztons\u00e1goss\u00e1g\u00e1nak pontosabb meg\u00edt\u00e9l\u00e9s\u00e9hez.\n                    <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n                    A nemzetk\u00f6zi Emp-Activity vizsg\u00e1lat\n                    magyarorsz\u00e1gi kohorsz\u00e1ban az empagliflozinkezel\u00e9s \u00e9letmin\u0151s\u00e9gre \u00e9s funkcion\u00e1lis\n                    statusra gyakorolt hat\u00e1s\u00e1nak \u00e9rt\u00e9kel\u00e9se, valamint biztons\u00e1goss\u00e1g\u00e1nak vizsg\u00e1lata\n                    a sz\u00edvel\u00e9gtelens\u00e9g spektrum\u00e1ban.\n                    <jats:italic>M\u00f3dszer:<\/jats:italic>\n                    A prospekt\u00edv,\n                    beavatkoz\u00e1ssal nem j\u00e1r\u00f3, multicentrikus megfigyel\u00e9ses vizsg\u00e1latba 11 hazai\n                    centrumb\u00f3l \u00f6sszesen 106, t\u00fcnetes sz\u00edvel\u00e9gtelen beteg ker\u00fclt bevon\u00e1sra, akik\n                    k\u00f6z\u00fcl 101 az empagliflozint kap\u00f3 kohorszba, 5 beteg pedig a nem empagliflozint\n                    kap\u00f3 kohorszba ker\u00fclt. A betegek a rutin-sz\u00edvel\u00e9gtelens\u00e9gter\u00e1pia r\u00e9szek\u00e9nt\n                    empagliflozinkezel\u00e9st kaptak, \u00e9s a vizsg\u00e1lat kezdet\u00e9n, valamint 24 h\u00e9t\n                    eltelt\u00e9vel kit\u00f6lt\u00f6tt\u00e9k a Kansas City Cardiomyopathy Questionnaire (KCCQ-12)\n                    k\u00e9rd\u0151\u00edvet. A funkcion\u00e1lis statust a New York Heart Association (NYHA)\n                    oszt\u00e1lyoz\u00e1sa alapj\u00e1n \u00e9rt\u00e9kelt\u00e9k.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    A vizsg\u00e1lat\n                    empagliflozinkohorsz\u00e1ba bevont 101 beteg medi\u00e1n\u00e9letkora 69 \u00e9v volt, 28,7%-uk n\u0151,\n                    funkcion\u00e1lis st\u00e1diumuk NYHA II. \u00e9s III. A betegek 57%-a a HFrEF-, 19%-a HFmrEF-,\n                    22%-a pedig a HFpEF-fenot\u00edpusba tartozott. A sz\u00edvel\u00e9gtelens\u00e9g h\u00e1tter\u00e9ben a\n                    leggyakrabban (42%) ischaemi\u00e1s etiol\u00f3gia \u00e1llt. A leggyakoribb t\u00e1rsbetegs\u00e9gek a\n                    hypertonia (58%), a pitvarfibrill\u00e1ci\u00f3 (33%), a cukorbetegs\u00e9g (26%) \u00e9s a\n                    hyperlipidaemia (25%) voltak. A KCCQ-12 \u00f6sszpontsz\u00e1m\u00e1ban jelent\u0151s javul\u00e1s volt\n                    megfigyelhet\u0151 (74,3 \u00b1 19,5\n                    <jats:italic>vs.<\/jats:italic>\n                    67,1 \u00b1 19,5 pont, p&lt;0,01).\n                    Klinikailag szignifik\u00e1ns javul\u00e1s (\u22655 pontos n\u00f6veked\u00e9s) a betegek 53%-\u00e1ban\n                    k\u00f6vetkezett be. A NYHA-st\u00e1dium jelent\u0151sen javult. A systol\u00e9s v\u00e9rnyom\u00e1s cs\u00f6kkent\n                    (131 \u00b1 16 Hgmm\n                    <jats:italic>vs.<\/jats:italic>\n                    127 \u00b1 17 Hgmm, p = 0,02), m\u00edg a diastol\u00e9s\n                    v\u00e9rnyom\u00e1s, a sz\u00e9rumkreatinin- \u00e9s -k\u00e1liumszint nem v\u00e1ltozott a 24 hetes kezel\u00e9s\n                    sor\u00e1n.\n                    <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    A sz\u00edvel\u00e9gtelens\u00e9gben szenved\u0151\n                    magyarorsz\u00e1gi betegek k\u00f6r\u00e9ben a 24 hetes empagliflozinkezel\u00e9s az \u00e9letmin\u0151s\u00e9g \u00e9s\n                    a funkcion\u00e1lis kapacit\u00e1s szignifik\u00e1ns javul\u00e1s\u00e1val j\u00e1rt, emellett a kezel\u00e9s j\u00f3l\n                    toler\u00e1lhat\u00f3nak bizonyult. A vizsg\u00e1lat eredm\u00e9nyei meger\u0151s\u00edtik az empagliflozin\n                    alkalmaz\u00e1s\u00e1nak hat\u00e9konys\u00e1g\u00e1t \u00e9s biztons\u00e1goss\u00e1g\u00e1t a mindennapi klinikai\n                    gyakorlatban. Orv Hetil. 2026; 167(7): 257\u2013264.\n                  <\/jats:p>","DOI":"10.1556\/650.2026.33487","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:16:07Z","timestamp":1771200967000},"page":"257-264","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Az empagliflozin hat\u00e1sa a sz\u00edvel\u00e9gtelens\u00e9gben szenved\u0151 betegek \u00e9letmin\u0151s\u00e9g\u00e9re: a nemzetk\u00f6zi Emp-Activity vizsg\u00e1lat magyar kohorsz\u00e1nak eredm\u00e9nyei"],"prefix":"10.1556","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-8405","authenticated-orcid":true,"given":"Arnold P\u00e9ter","family":"R\u00e1duly","sequence":"first","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Kardiol\u00f3giai Int\u00e9zet, Kardiol\u00f3giai Tansz\u00e9k Debrecen, M\u00f3ricz Zs. krt. 22., 4032 Magyarorsz\u00e1g"},{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Kardiol\u00f3giai Int\u00e9zet, Klinikai Fiziol\u00f3giai Tansz\u00e9k Debrecen Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Borb\u00e9ly","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Kardiol\u00f3giai Int\u00e9zet, Kardiol\u00f3giai Tansz\u00e9k Debrecen, M\u00f3ricz Zs. krt. 22., 4032 Magyarorsz\u00e1g"},{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Kardiol\u00f3giai Int\u00e9zet, Klinikai Fiziol\u00f3giai Tansz\u00e9k Debrecen Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Szil\u00e1gyi","sequence":"additional","affiliation":[{"name":"Heves V\u00e1rmegyei Markhot Ferenc Oktat\u00f3k\u00f3rh\u00e1z \u00e9s Rendel\u0151int\u00e9zet, Kardiol\u00f3giai Oszt\u00e1ly Eger Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Shahim B, Kapelios CJ, Savarese G, et al. Global public health\n                    burden of heart failure: an updated review. Card Fail Rev. 2023; 9: e11.\n                        https:\/\/doi.org\/10.15420\/cfr.2023.05","DOI":"10.15420\/cfr.2023.05"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"LaMonte MJ. Physical activity and heart failure: taking steps to\n                    control a major public health burden. Am J Lifestyle Med. 2018; 14: 555-570.\n                        https:\/\/doi.org\/10.1177\/1559827618769609","DOI":"10.1177\/1559827618769609"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"T\u00f3th \u00c1A, Sinka FM, Belicza \u00c9, et al. Determinants of short-term\n                    mortality in patients with heart failure in Hungary. Findings from a\n                    retrospective follow-up study based on administrative data. [Sz\u00edvel\u00e9gtelens\u00e9gben\n                    szenved\u0151 betegek r\u00f6vid t\u00e1v\u00fa hal\u00e1loz\u00e1s\u00e1t befoly\u00e1sol\u00f3 t\u00e9nyez\u0151k haz\u00e1nkban. Egy\n                    adminisztrat\u00edv adatokon alapul\u00f3 retrospekt\u00edv k\u00f6vet\u00e9ses vizsg\u00e1lat eredm\u00e9nyei.]\n                    Orv Hetil. 2025; 166: 1653-1665. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2025.33398","DOI":"10.1556\/650.2025.33398"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Stolfo D, Lund LH, Benson L, et al. Persistent high burden of heart\n                    failure across the ejection fraction spectrum in a nationwide setting. J Am\n                    Heart Assoc. 2022; 11: e026708.\n                        https:\/\/doi.org\/10.1161\/JAHA.122.026708","DOI":"10.1161\/JAHA.122.026708"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and\n                    one-year outcomes in patients with chronic heart failure and preserved,\n                    mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure\n                    Long-term Registry. Eur J Heart Fail. 2017; 19:1574-1585.\n                        https:\/\/doi.org\/10.1002\/ejhf.813","DOI":"10.1002\/ejhf.813"},{"key":"R6","unstructured":"Horv\u00e1th L, Tomcs\u00e1nyi J, T\u00f3th E. Epidemiology and therapeutic\n                    practice of heart failure: Hungarian experiences based on data bases. [A\n                    sz\u00edvel\u00e9gtelens\u00e9g epidemiol\u00f3gi\u00e1ja \u00e9s ter\u00e1pi\u00e1s gyakorlata: hazai tapasztalatok a\n                    finansz\u00edroz\u00e1si adatb\u00e1zisok feldolgoz\u00e1s\u00e1val.] Innov\u00e1ci\u00f3 Menedzsment Eg\u00e9szs\u00e9g\u00fcgy\n                    2012: 11: 46-50. [Hungarian]"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Nyolczas N, Heltai K, Borb\u00e9ly A, et al. Hungarian Heart Failure\n                    Registry 2015-2016. Preliminary results. [Magyar sz\u00edvel\u00e9gtelens\u00e9g regiszter\n                    2015-2016: kezdeti eredm\u00e9nyek.] Orv Hetil. 2017; 158: 94-100. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2017.30671","DOI":"10.1556\/650.2017.30671"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Beghini A, Sammartino AM, Papp Z, et al. 2024 update in heart\n                    failure. ESC Heart Fail. 2025; 12: 8-42.\n                        https:\/\/doi.org\/10.1002\/ehf2.14857","DOI":"10.1002\/ehf2.14857"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the\n                    diagnosis and treatment of acute and chronic heart failure. Developed by the\n                    Task Force for the diagnosis and treatment of acute and chronic heart failure of\n                    the European Society of Cardiology (ESC). With the special contribution of the\n                    Heart Failure Association (HFA) of the ESC. Eur Heart J Fail. 2022; 24: 4-131.\n                        https:\/\/doi.org\/10.1002\/ejhf.2333","DOI":"10.1002\/ejhf.2333"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Muk B, Pilecky D, B\u00e1nfi-Bacs\u00e1rdi F, et al. The change in the\n                    pharmacotherapy of heart failure with reduced ejection fraction and its effect\n                    on prognosis: experience in the Hungarian clinical practice. [A cs\u00f6kkent\n                    ejekci\u00f3s frakci\u00f3j\u00fa sz\u00edvel\u00e9gtelens\u00e9g gy\u00f3gyszeres kezel\u00e9s\u00e9nek v\u00e1ltoz\u00e1sa \u00e9s a\n                    progn\u00f3zisra gyakorolt hat\u00e1sa a hazai gyakorlatban.] Orv Hetil. 2024; 165:\n                    698-710. [Hungarian]\n                    https:\/\/doi.org\/10.1556\/650.2024.33045","DOI":"10.1556\/650.2024.33045"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Girardi AC, Polidoro JZ, Castro PC, et al. Mechanisms of heart\n                    failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic\n                    conditions. Am J Physiol Cell Physiol. 2024; 327: C525-C544.\n                        https:\/\/doi.org\/10.1152\/ajpcell.00143.2024","DOI":"10.1152\/ajpcell.00143.2024"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Lin Y, Zhang H, Zhao S, et al. The efficacy and safety of the\n                    combined therapy of sodium-glucose co-transporter-2 inhibitors and angiotensin\n                    receptor-neprilysin inhibitor in patients with heart failure with reduced\n                    ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF. Front\n                    Cardiovasc Med. 2022; 9: 882089.\n                        https:\/\/doi.org\/10.3389\/fcvm.2022.882089","DOI":"10.3389\/fcvm.2022.882089"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal\n                    outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383:\n                    1413-1424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","DOI":"10.1056\/NEJMoa2022190"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in\n                    patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;\n                    381: 1995-2008.\n                    https:\/\/doi.org\/10.1056\/NEJMoa1911303","DOI":"10.1056\/NEJMoa1911303"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart\n                    failure with a preserved ejection fraction. N Engl J Med. 2021; 385: 1451-1461.\n                        https:\/\/doi.org\/10.1056\/NEJMoa2107038","DOI":"10.1056\/NEJMoa2107038"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Solomon SD, de Boer RA, DeMets D, et al. Dapagliflozin in heart\n                    failure with preserved and mildly reduced ejection fraction: rationale and\n                    design of the DELIVER trial. Eur J Heart Fail. 2021; 23: 1217-1225.\n                        https:\/\/doi.org\/10.1002\/ejhf.2249","DOI":"10.1002\/ejhf.2249"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Thompson A, Fleischmann KE, Smilowitz NR, et al. 2024\n                    AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative\n                    cardiovascular management for noncardiac surgery: a report of the American\n                    College of Cardiology\/American Heart Association joint committee on clinical\n                    practice guidelines. Circulation 2024; 150: e351-e442.\n                        https:\/\/doi.org\/10.1161\/CIR.0000000000001298","DOI":"10.1161\/CIR.0000000000001298"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 Focused update of the\n                    2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart\n                    failure: developed by the task force for the diagnosis and treatment of acute\n                    and chronic heart failure of the European Society of Cardiology (ESC) with the\n                    special contribution of the Heart Failure Association (HFA) of the ESC. Eur\n                    Heart J. 2023; 44: 3627-3639.\n                        https:\/\/doi.org\/10.1093\/eurheartj\/ehad195","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Spertus JA, Jones PG, Sandhu AT, et al. Interpreting the Kansas City\n                    Cardiomyopathy Questionnaire in clinical trials and clinical care. JACC\n                    State-of-the-Art Review. J Am Coll Cardiol. 2020; 76: 2379-2390.\n                        https:\/\/doi.org\/10.1016\/j.jacc.2020.09.542","DOI":"10.1016\/j.jacc.2020.09.542"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Spertus JA, Jones PG. Development and validation of a short version\n                    of the Kansas City Cardiomyopathy Questionnaire. Circ Cardiovasc Qual Outcomes\n                    2015; 8: 469-476.\n                    https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.115.001958","DOI":"10.1161\/CIRCOUTCOMES.115.001958"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"de Souza MM, Defante ML, de Athayde de Hollanda Morais BA, et al.\n                    Effects of SGLT2 inhibitors on health-related quality of life and functional\n                    capacity in patients with heart failure with and without diabetes: a\n                    meta-analysis of randomized controlled trials. Int J Clin Pharm. 2025; 47:\n                    654-665. https:\/\/doi.org\/10.1007\/s11096-025-01908-0","DOI":"10.1007\/s11096-025-01908-0"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Ho JE, Redfield MM, Lewis GD, et al. Deliberating the diagnostic\n                    dilemma of heart failure with preserved ejection fraction. Circulation 2020;\n                    142: 1770-1780.\n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.041818","DOI":"10.1161\/CIRCULATIONAHA.119.041818"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Van Dalen BM, Chin JF, Motiram PA, et al. Challenges in the\n                    diagnosis of heart failure with preserved ejection fraction in individuals with\n                    obesity. Cardiovasc Diabetol. 2025; 24: 71.\n                        https:\/\/doi.org\/10.1186\/s12933-025-02612-z","DOI":"10.1186\/s12933-025-02612-z"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor\n                    empagliflozin in patients hospitalized for acute heart failure: a multinational\n                    randomized trial. Nat Med. 2022; 28: 568-574.\n                        https:\/\/doi.org\/10.1038\/s41591-021-01659-1","DOI":"10.1038\/s41591-021-01659-1"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Berg DD, Patel SM, Haller PM, et al. Dapagliflozin in patients\n                    hospitalized for heart failure: primary results of the DAPA ACT HF-TIMI 68\n                    randomized clinical trial and meta-analysis of sodium-glucose cotransporter-2\n                    inhibitors in patients hospitalized for heart failure. Circulation 2025; 152:\n                    1411-1422.\n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.076575","DOI":"10.1161\/CIRCULATIONAHA.125.076575"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Lindberg F, Lund LH, Benson L, et al. Trajectories in New York Heart\n                    Association functional class in heart failure across the ejection fraction\n                    spectrum: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2022;\n                    24: 2093-2104. Erratum: Eur J Heart Fail. 2023; 25: 444.\n                        https:\/\/doi.org\/10.1002\/ejhf.2644","DOI":"10.1002\/ejhf.2644"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Tomaszuk-Kazberuk A, Hermann M, et al. Impact of empagliflozin on\n                    quality-of-life in real-world patients with heart failure: insights from the\n                    multinational Emp-Activity study. Eur Heart J. 2025; 46(Suppl 1): ehaf784.\n                        https:\/\/doi.org\/10.1093\/eurheartj\/ehaf784.1218","DOI":"10.1093\/eurheartj\/ehaf784.1218"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/7\/article-p257.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/7\/article-p257.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/7\/article-p257.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:41:53Z","timestamp":1785508913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/7\/article-p257.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":27,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33487","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}